Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline - Test2 - elhamkhani - TriplyDB

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

http://www.wikidata.org/entity/Q34604979

about

Screening for prostate cancer Screening for prostate cancer 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer Long-term survival of participants in the prostate cancer prevention trial.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?Hormonal therapy in metastatic prostate cancer: current perspectives and controversies Finasteride and prostate cancer: a commentary Recent advances in prostate development and links to prostatic diseases What we have learned from randomized trials of prostate cancer screening.Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications Prostate cancer prevention: concepts and clinical recommendations.Prevention strategies in prostate cancer.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it.Off-label drug use in oncology: a systematic review of literature.A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer.Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia.Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance.What's wrong with chemoprevention of prostate cancer?Prostate Cancer Prevention: Do the 5-ARIs Make the Grade?

P2860

Q24201690-3E05D124-3B66-4E20-91D4-5360BAD86EBA Q24245476-48BC85C2-0C9C-4317-BE33-A96306C38265 Q34005866-738985CF-D855-4505-AD03-5D601F7109E8 Q34077860-6053F33F-CED6-4DF7-A949-2870911C0514 Q34130128-786EF9CB-25AC-4E9B-890D-9A05082976A3 Q34284547-3E8A5E0F-2577-4CD0-855F-39FAF0A4941E Q34313221-0E83F6A8-A7E0-42BD-930F-8227ADBD1A59 Q34362184-A599E557-E075-47D3-A490-9BFECC9D7D73 Q34511194-E76822DD-6CCF-4B7D-A44E-9071698EC727 Q35111934-70CFCF9D-F7F0-45B1-A8CE-339E7A5C0F8F Q35569303-D1205BCB-4B0B-4020-B5D2-76EBC919342C Q36102792-A3BC9B11-F8A2-48B2-BE15-1224FCD6F351 Q36642727-4B3E5530-E01C-4CA1-8164-BBC36D53F182 Q37084639-D68C829D-7A82-48CB-8856-42966B4F3D56 Q37639218-2EC57E5C-3E16-49DF-87A4-6402BFC26C44 Q37766754-52E179DD-82BB-4310-BE8E-1F6D4F580E8E Q37794799-8E0C25CA-88FC-4F4A-BE01-2CEA611B7107 Q37818297-90D74168-D43D-4814-9D5A-31229894C2CC Q37968148-DD01E382-3451-427A-9BB6-0243C71F1E59 Q38125607-AD5CD12A-A7C6-4BEF-9F6E-A9DC5B5570B8 Q38977535-82257B86-8524-42D0-9FB0-49E2DE28555F Q39768137-B3C4AE54-267B-446F-9F60-13E946BA0091 Q50294307-811AAAE4-D7BD-4350-8048-EDCF60DE1CBF Q52670853-74CDF741-3C71-4890-908E-80E700CFC302 Q56775830-2B18C4A7-E2AA-4ED3-A015-3DDB208436BD Q57989222-E5191D5A-FC51-4CF2-992E-8D94C18C6929

P2860

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

http://www.wikidata.org/entity/Q34604979

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@ast

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@en

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@nl

type

label

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@ast

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@en

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@nl

prefLabel

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@ast

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@en

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@nl

P1433

Q34604979-3127C32B-BE07-4705-BBDF-509674C16FC2

P1476

Q34604979-F4D5487B-714E-4A35-9B4A-6FFADC20C41C

P2093

Q34604979-11E5CBD9-535B-46BF-A019-7837B9059AC7

Q34604979-3919ABE1-BC0B-41A9-823E-94DB0E6786CC

Q34604979-3D524670-DF31-4FDC-AF77-820960481189

Q34604979-45053E26-087D-45D5-ADF4-C9008A8B02EE

Q34604979-500FCA63-6ACE-4B51-91D3-CD0131B057D1

Q34604979-5177C412-346D-421D-8E3D-54A24A92D6EA

Q34604979-53411407-80F3-492B-928D-0DE0F5849E24

Q34604979-5C2C5931-47CF-4500-A63F-67C120DE38B0

Q34604979-6E414CC6-23A9-4E97-8EE4-51CF5BCBEFBD

Q34604979-84B607D4-6D63-4729-BDE7-AC5B06093B43

P2860

Q34604979-036E790D-3936-4EB1-8D2F-DE07BAD6475E

Q34604979-042D3135-3286-413A-89BE-752DAC8D92F5

Q34604979-05CD0DF8-DF04-4644-AFF5-495F212E4D44

Q34604979-05D7CBD7-2202-4C1E-B163-48584E04ABC9

Q34604979-0B20D96E-4D84-4487-9C19-FBD5D802A0CA

Q34604979-23AEB397-9004-414D-8CAC-5884C48174E3

Q34604979-24EC6FD5-5AA9-41A6-96C1-6B886ADA3A22

Q34604979-2758D321-610F-412F-B509-7D150141842D

Q34604979-3401A544-BDD0-40F9-9CC0-B07D797E6EF2

Q34604979-35DCAC03-4276-4189-B88B-2751B70E2376

P304

Q34604979-A19C00B9-A22E-4CA6-B81B-516A9DCF3A45

P31

Q34604979-CA654F82-5705-4CB8-936C-324320F55331

P356

Q34604979-1C024E8D-FD05-4CF8-BDBE-50ECBD48A163

P407

Q34604979-EB8809BD-7E49-4F55-A7B4-D2464B228701

P433

Q34604979-BB7CF10F-6F7A-46ED-91B8-D54C19D827A1

P478

Q34604979-386FAECC-A15A-446C-9479-F35E42D4FF53

P50

Q34604979-D2BBEB8F-F880-4D03-8BFA-F57E91DAF47F

P577

Q34604979-54B66E3A-92F7-4002-AB4E-4688A32FABEC

P698

Q34604979-67B8F9EF-D009-450C-8C7F-BFD8040F2FA4

P932

Q34604979-BC86DD6D-CFCD-4942-993C-D6372A20BCF3

P356

JCO.2008.16.9599

P1433

Journal of Clinical Oncology

P1476

Use of 5-alpha-reductase inhib ...... 08 Clinical Practice Guideline

@en

P2093

American Society of Clinical Oncology Health Services Committee

http://www.w3.org/2001/XMLSchema#string

American Urological Association Practice Guidelines Committee

http://www.w3.org/2001/XMLSchema#string

Barnett S Kramer

http://www.w3.org/2001/XMLSchema#string

H Ballentine Carter

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Joseph P Costantino

http://www.w3.org/2001/XMLSchema#string

Karen L Hagerty

http://www.w3.org/2001/XMLSchema#string

Mark R Somerfield

http://www.w3.org/2001/XMLSchema#string

Paul A Godley

http://www.w3.org/2001/XMLSchema#string

Paul Schellhammer

http://www.w3.org/2001/XMLSchema#string

P2860

5-alpha-reductase inhibitors for prostate cancer prevention

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

P304

1502-1516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.16.9599

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19252137

http://www.w3.org/2001/XMLSchema#string

P932

2668556

http://www.w3.org/2001/XMLSchema#string